Spain TV Ratings: ‘Casados a Primera Vista’ Wins, ‘El Precio Justo’ Weak Start
- PROGRAMAS CON MEJOR CUOTA DEL LUNES (POR CADENAS)
|
La 1: |
*Programas emitidos entre las 07:30 y las 01:00 horas
“Pasapalabra” (Antena 3), a las 21:02 con 3.501.890 espectadores y un 28.1% de share I am sorry, but the provided text appears to be a fragment of an HTML table, specifically data related to percentages and labels like “Autonómicas (FORTA)” and “Temáticas de pago”. It is indeed not a complete HTML article body. Therefore,I cannot fulfill the request to “Return ONLY the final HTML article body”. If you provide the *entire* HTML document, I will gladly extract the ` ` content for you.
I am sorry, but the provided text appears to be incomplete and lacks the structure of a typical HTML article body. it seems to be fragments of a table, likely representing data about shares or ownership percentages. I cannot construct a meaningful HTML article from this. To fulfill your request, I need a complete and well-formed HTML document or a text that can be reasonably interpreted as an article.
SOBREMESA
| ||||||||||||||||
|
Informativos Telecinco 15h |
9.8% |
1.049.000 |
|||||||||||||||
|
laSexta Noticias 14h |
9% |
El Desmarque Cuatro 1 |
4.6% |
481.000 |
|||||||||||||
Antena 3 Noticias 2
16.8%
2.752.000
Telediario 2
14.1%
1.872.000
laSexta Noticias 20h
.
Inflation Reduction Act: Lowering Prescription Drug Costs
Table of Contents
The inflation Reduction Act of 2022 (IRA) substantially altered the landscape of prescription drug pricing in the United States, allowing Medicare to negotiate prices for certain high-expenditure drugs and capping out-of-pocket costs for beneficiaries. This legislation represents a major shift in federal policy, aiming to increase access to affordable medications.
Medicare Drug Price Negotiation
The Inflation Reduction act empowers Medicare to directly negotiate the prices of certain prescription drugs with pharmaceutical companies, a power previously prohibited. This negotiation process began in 2023, with negotiated prices taking effect in 2026.
The initial 10 drugs selected for negotiation in 2023 represent some of the most costly medications under Medicare Part D. The Centers for Medicare & Medicaid Services (CMS) released the list on August 29,2023,including drugs like Eliquis (apixaban) for preventing blood clots,Jardiance (empagliflozin) for diabetes,and Stelara (ustekinumab) for autoimmune disorders. Negotiations are conducted annually, with additional drugs added to the list over time.
Example: On March 14, 2024, CMS announced the initial negotiated prices for these 10 drugs, resulting in estimated savings of $9.1 billion annually for Medicare beneficiaries. details of the negotiated prices are available on the CMS website.
How Negotiation Works
The negotiation process involves CMS engaging with pharmaceutical manufacturers to determine a “maximum fair price” for selected drugs. This price is based on factors including research and development costs, production and distribution expenses, and existing market data. Manufacturers who refuse to negotiate or fail to agree to a fair price may face excise taxes or withdrawal of Medicare coverage. The full text of the Inflation Reduction Act outlines the specific negotiation parameters.
out-of-Pocket Cost Caps for Medicare Beneficiaries
The IRA also introduced a $2,000 annual out-of-pocket spending cap for prescription drugs under Medicare Part D,beginning in 2025. This cap applies to covered drugs and includes both brand-name and generic medications.
Prior to the IRA, medicare beneficiaries faced perhaps unlimited out-of-pocket costs for prescription drugs, leading to financial hardship for many individuals with chronic conditions.The $2,000 cap provides significant financial relief, particularly for those requiring expensive medications.
Evidence: According to a Kaiser Family Foundation (KFF) analysis, approximately 3.3 million Medicare beneficiaries spent more than $2,000 out-of-pocket on prescription drugs in 2020. These beneficiaries will directly benefit from the new cap.
Impact on Insulin Costs
A key provision of the IRA specifically addresses the cost of insulin for Medicare beneficiaries.Beginning in 2023, the law capped the monthly cost of insulin at $35 for those enrolled in Medicare Part D. This provision was initially limited to those in the Part D coverage gap, but was expanded to all Medicare beneficiaries in 2024. The White House released a fact sheet detailing the insulin cost cap and its benefits.
Pharmaceutical Industry response & Legal Challenges
The pharmaceutical industry has actively opposed the IRA’s drug pricing provisions, arguing that they will stifle innovation and reduce investment in research and development. Several pharmaceutical companies and industry groups have filed lawsuits challenging the constitutionality of the law.
Legal Challenge: The U.S. Supreme Court rejected a challenge to the IRA on March 4, 2024, allowing the drug price negotiation process to proceed. The court found that the pharmaceutical companies lacked standing to sue.
Potential effects on Innovation
Critics argue that reduced revenue from drug price negotiation could lead to decreased investment in the development of new medications. Though, proponents contend that the IRA strikes a balance between affordability and innovation, allowing pharmaceutical companies to continue to profit while ensuring that patients have access to life-saving drugs at reasonable prices. The long-term effects on pharmaceutical innovation remain to be seen.